Boehringer Ingelheim is a research-driven pharmaceutical company, involved in basic research and is committed to improving HIV therapy by providing physicians and patients with innovative antiretrovirals.
Boehringer-Ingelheim is contributing to the fight against HIV/AIDS in the developing world through manifold activities which all serve the ultimate goal of providing access to affordable medicines.
Since July 2000, Viramune® has been made available free of charge to developing countries for the prevention of Mother-To-Child-Transmission of HIV-1 (pMTCT) through the Viramune® Donation Programme.
Boehringer Ingelheim donates Viramune® in accordance with the WHO Guidelines for Drug donations based on the expressed interest of governments, NGOs, charitable organisations or other healthcare providers with comprehensive pMTCT.
Most of the programmes are in Sub-Saharan Africa (e.g. South Africa, Zambia, Kenya), but also in Eastern Europe (e.g. Ukraine, Russia), Latin-America (e.g. Peru, Ecuador) and in Asia (e.g. China, Vietnam) and many more are currently under review.
In resource poor settings the Viramune Donation Programme has been a catalyst for local developments of healthcare infrastructures. Therefore Boehringer Ingelheim and WHO recognize the potential for pMTCT sites to serve as entry points for the introduction of chronic ARV therapy. Further information at http://www.pmtctdonations.org/.
The success of these access programmes has been made possible through multiple partnerships with private and governmental organisations both locally (e.g. with African First Ladies organisations) and internationally (e.g. with the German Society for Technological Cooperation, GTZ). On the local level, cooperations have been strengthened with many key health care implementers such as AXIOS, the International Council of Nurses, Elisabeth Glaser Pediatric AIDS Foundation and UNICEF.